Please login to the form below

Not currently logged in
Email:
Password:

Vytorin

This page shows the latest Vytorin news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.

Latest news

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics